Published in Am J Hypertens on September 08, 2016
Water-only Fasting in the Treatment of Hypertension Patients | NCT04515095
Rapid Screening of Primary Aldosteronism by a Novel Chemiluminescent Immunoassay. Hypertension (2017) 0.75
Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension (2007) 5.61
Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens (2003) 2.54
Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension (2011) 2.51
Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension (2002) 2.46
Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens (2004) 1.75
Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A (2003) 1.74
Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation (2000) 1.70
Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med (2008) 1.68
Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension (2012) 1.63
Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system. J Hypertens (2010) 1.62
Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status. J Hypertens (2016) 1.43
Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens (2002) 1.36
Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens (2003) 1.35
Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis (2001) 1.31
Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension (2009) 1.28
Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation (2004) 1.28
The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens (2002) 1.24
A novel adipokine CTRP1 stimulates aldosterone production. FASEB J (2008) 1.20
Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension (2008) 1.10
Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens (2008) 1.03
Effect of spironolactone in resistant arterial hypertension: a randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT). Medicine (Baltimore) (2014) 0.96
Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension. Hypertension (2016) 0.90
Refractory versus resistant hypertension: Novel distinctive phenotypes. J Nat Sci (2017) 0.75
Spironolactone versus renal nerve denervation for treatment of uncontrolled resistant hypertension. J Hypertens (2016) 0.75